GE HealthCare Stock Surges 132.45% in Trading Volume Ranking 98th

On April 30, 2025, GE's trading volume surged to 9.00 billion, marking a 132.45% increase from the previous day, placing it at the 98th position in the day's trading volume rankings. GE HealthCare, a subsidiary of GE, reported a 3.29% increase in stock price, marking two consecutive days of gains with a total increase of 3.32% over the past two days.

GE HealthCare reported its first-quarter 2025 financial results, highlighting a 3% year-over-year revenue growth and a 4% organic revenue growth. The company's net income margin improved to 11.8% from 8.0% in the prior year, while the adjusted earnings before interest and taxes (EBIT) margin stood at 15.0% compared to 14.7% the previous year. Diluted earnings per share (EPS) were $1.23, up from $0.81 the prior year, with adjusted EPS at $1.01 compared to $0.90.

The company's cash flow from operating activities was $250 million, down from $419 million the previous year, with free cash flow at $98 million, a decrease from $274 million. GE HealthCare updated its full-year 2025 guidance, reflecting the impact of announced tariffs, and authorized a $1 billion share repurchase program. The company's President and CEO, Peter Arduini, emphasized the strong execution and robust revenue, orders, and profit growth driven by the U.S. market. He also highlighted the company's focus on precision care and growth acceleration strategies, including the acquisition of Nihon Medi-Physics to enhance global access to next-generation radiopharmaceuticals.

In terms of segment performance, the Imaging segment reported revenues of $2.14 billion, with a 4% year-over-year growth and a 5% organic growth. The Advanced Visualization Solutions segment saw revenues of $1.24 billion, with a 1% year-over-year growth and a 3% organic growth. The Patient Care Solutions segment reported revenues of $753 million, with a 1% year-over-year growth and a 2% organic growth. The Pharmaceutical Diagnostics segment had revenues of $632 million, with a 6% year-over-year growth and an 8% organic growth.

GE HealthCare continues to invest in innovation and growth, with recent highlights including the launch of Flyrcado™ (flurpiridaz F 18) injection in the U.S., the acquisition of Nihon Medi-Physics, and the unveiling of the Revolution™ Vibe CT system with Unlimited One-Beat Cardiac imaging and AI solutions. The company's strategic investments and focus on advancing care pathways, particularly in cardiology, position it well for long-term growth and value creation.